IPO Acceleron Pharma (XLRN) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. Their research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, key regulators in the growth and repair of tissues throughout the human body. Acceleron has three internally discovered protein therapeutic candidates that are currently being studied in 12 ongoing Phase 2 clinical trials.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment